Saturday 17 October 2026
Export TECX’s income statement to Excel — free account
Tectonic Therapeutic, Inc.
TECX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 10.3%, free cash flow fell 46.7% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.65
0.65
−3.05%
Follow TECX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
29.15 | 26.63 | 18.51 | 22.29 |
Net Debt/EBITDA |
12.48 | 12.01 | 8.77 | 9.49 | |
Debt/Assets |
0.04% | 0.02% | 0.01% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.94 | 0.75 | 0.73 | 0.96 | |
Capex/Depreciation |
(0.49) | 0.00 | (0.06) | (0.21) | |
Interest Coverage |
(1,563.57) | (1,793.00) | (3,412.62) | (4,036.33) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.96) | (0.79) | (0.98) | (1.13) | |
Cash per Share |
14.38 | 13.88 | 12.62 | 11.97 | |
Shareholders Equity per Share |
14.30 | 13.72 | 12.28 | 11.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.30 | 13.72 | 12.28 | 11.80 | |
Free Cash Flow |
(17.98) | (14.46) | (18.43) | (21.51) | |
Working Capital |
263.87 | 247.69 | 226.93 | 220.73 | |
Capital Expenditures |
(0.17) | 0.00 | (0.02) | (0.06) | |
Net Current Asset Value |
263.77 | 247.65 | 223.73 | 217.91 | |
| Other line items | |||||
Quick Ratio |
28.70 | 26.32 | 18.28 | 21.90 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.95) | (0.79) | (0.98) | (1.13) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.06 | 1.03 | 4.40 | 2.24 | |
Average Assets |
222.86 | 206.97 | 280.70 | 266.17 | |
Average Common Equity |
208.94 | 196.05 | 265.73 | 253.81 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates